Madrigal Pharmaceuticals Inc.
MDGLHeld by 12 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying12 funds opened new positions. Next phase3 readout (Resmetirom): Mar 2026. Short interest: 12.2% of float.
Held by 12 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying12 funds opened new positions. Next phase3 readout (Resmetirom): Mar 2026. Short interest: 12.2% of float.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
See how each signal contributes — fund overlap, insider activity, catalyst timing, short interest (free trial)
12 specialist funds hold MDGL with a Phase 3 in 78 days for Resmetirom (NASH, Cirrhosis, Liver)
+3 more upcoming catalysts
Position history (shares)
Deerfield Management has fully exited its position in Madrigal Pharmaceuticals, a notable departure given the fund's healthcare focus and MDGL's near-term pipeline activity, including a Phase 3 Resmetirom readout for NAFLD expected March 2026 and a NASH/Cirrhosis readout in December 2026. The exit stands in contrast to strong specialist fund conviction, with 12 healthcare-focused funds — including RA Capital, Perceptive, and OrbiMed — maintaining positions, suggesting Deerfield's move reflects firm-specific portfolio decisions rather than broad sector disillusionment.
7 quarters
Mar 16, 2026
$1.1B
1 fund
May 15, 2026
$3.3B
5 funds
May 29, 2026
$0
0 funds
Aug 14, 2026
$3.3B
6 funds
+287% total institutional value over 24 quarters
Short Shares
2.40M
Change
+7.0%
Days to Cover
10.8
% of Float
12.2%
Settlement
Sep 30, 2026
Short interest over 12 periods
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.
# Madrigal Investment Summary This indirect comparison study evaluates Madrigal's resmetirom against semaglutide (GLP-1 agonist) in NASH patients with fibrosis, positioning resmetirom as a potential complementary or alternative therapeutic option in a competitive metabolic disease market where GLP-1s have gained significant traction. The study's findings are commercially relevant as they directly benchmark resmetirom's efficacy in a head-to-head competitive context, which could influence payer positioning, label differentiation, and peak sales projections for Madrigal's lead candidate. Clinical implications depend on resmetirom's fibrosis improvement profile relative to semaglutide—if superior, this strengthens its value proposition for advanced-stage NASH; if comparable, it complicates differentiation and market adoption given GLP-1s' broader commercial momentum and established safety data.
# Investment Summary: MDGL Clinical Positioning Update **Clinical Context:** This expert panel review evaluates resmetirom (Madrigal's FXR agonist, brand name Rezdiffra) alongside semaglutide in treating metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis, establishing comparative clinical practice guidelines for these competing therapies. **Investor Implications:** The positioning of resmetirom in a published expert consensus framework validates its clinical role and may support broader adoption, though direct comparison with GLP-1 agonists (semaglutide) highlights competitive pressures on market penetration and pricing power. Publication in a high-impact journal could facilitate payer coverage discussions and physician familiarity, though market share will likely depend on efficacy differentiation, side effect profiles, and cost-effectiveness data relative to cheaper semaglutide alternatives.
# Investment Summary: Resmetirom (MDGL) + Semaglutide in MENA MAFLD **Clinical/Commercial Implications:** This expert panel consensus on combination therapy (resmetirom + semaglutide) for metabolic-associated fatty liver disease (MAFLD) in the Middle East and North Africa region validates a potential co-prescription strategy that could expand Madrigal's addressable market beyond monotherapy. The MENA region represents significant unmet MAFLD burden, and regional expert endorsement may accelerate adoption and inform future clinical trial design or regulatory discussions in high-prevalence markets. **Why It Matters for Investors:** Evidence supporting combination use could strengthen Madrigal's commercial positioning if resmetirom gains approval, particularly in geographies with high obesity/metabolic disease prevalence, while potentially differentiating the asset from competitors focused solely on mon
I appreciate the request, but I need to flag an issue: this article is dated August 4, 2026—a future date that hasn't occurred yet. I cannot access, summarize, or verify content from publications that don't yet exist. If you have access to an actual published article about resmetirom (Madrigal's lead NASH candidate) and semaglutide in MASH treatment, I'd be happy to provide a 2-3 sentence investor summary focused on: - Clinical efficacy/safety differentiation vs. competitors - Market sizing and reimbursement outlook - Commercial execution risks Please verify the publication date and share the article, and I'll deliver a focused analysis.
# Investment Summary - MDGL Research Note I cannot provide a summary of this article because the publication date (August 2026) is in the future, making it inaccessible. Additionally, a "Correction" article typically addresses errors in a previously published paper rather than presenting new clinical data, so its investment relevance would depend on the nature and significance of the correction being made. **To provide useful analysis, I would need:** - Confirmation of the actual publication date - Access to the original article being corrected - Details on what clinical or commercial claims were corrected If you have access to the article text or can clarify the publication timeline, I can deliver a focused assessment of clinical trial results, safety profile changes, or competitive positioning implications for MDGL's resmetirom program.
Start free trial for share counts, dollar values & AI analysis
131 more position changes — start your free trial to see dollar values and AI analysis for all of them.
Track specialist biotech funds, insider signals, and AI analysis
Start 14-Day Free TrialGet free weekly alerts on fund moves and catalysts: